Nano-formulated curcumin (Lipodisq (TM)) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F19%3A00508402" target="_blank" >RIV/68378041:_____/19:00508402 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/19:10395499 RIV/00216208:11150/19:10395499 RIV/00179906:_____/19:10395499

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/abs/pii/S0028390819301674?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0028390819301674?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.neuropharm.2019.05.018" target="_blank" >10.1016/j.neuropharm.2019.05.018</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Nano-formulated curcumin (Lipodisq (TM)) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats

Popis výsledku v původním jazyce

A highly water soluble, nano-formulated curcumin was used for the treatment of the experimental model of spinal cord injury (SCI) in rats. Nanocurcumin and a vehicle nanocarrier as a control, were delivered both locally, immediately after the spinal cord injury, and intraperitoneally during the 4 consecutive weeks after SCI. The efficacy of the treatment was assessed using behavioral tests, which were performed during the experiment, weekly for 9 weeks. The behavioral tests (BBB, flat beam test, rotarod, motoRater) revealed a significant improvement in the nanocurcumin treated group, compared to the nanocarrier control. An immunohistochemical analysis of the spinal cord tissue was performed at the end of the experiment and this proved a significant preservation of the white matter tissue, a reduced area of glial scaring and a higher amount of newly sprouted axons in the nanocurcumin treated group. The expression of endogenous genes (Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, Nfk beta) and interleukins(IL-1 beta, TNF-alpha, IL-6, IL-12, CCL-5, IL-11, IL-10, IL-13) was evaluated by qPCR and showed changes in the expression of the inflammatory cytokines in the first two weeks after SCI.

Název v anglickém jazyce

Nano-formulated curcumin (Lipodisq (TM)) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats

Popis výsledku anglicky

A highly water soluble, nano-formulated curcumin was used for the treatment of the experimental model of spinal cord injury (SCI) in rats. Nanocurcumin and a vehicle nanocarrier as a control, were delivered both locally, immediately after the spinal cord injury, and intraperitoneally during the 4 consecutive weeks after SCI. The efficacy of the treatment was assessed using behavioral tests, which were performed during the experiment, weekly for 9 weeks. The behavioral tests (BBB, flat beam test, rotarod, motoRater) revealed a significant improvement in the nanocurcumin treated group, compared to the nanocarrier control. An immunohistochemical analysis of the spinal cord tissue was performed at the end of the experiment and this proved a significant preservation of the white matter tissue, a reduced area of glial scaring and a higher amount of newly sprouted axons in the nanocurcumin treated group. The expression of endogenous genes (Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, Nfk beta) and interleukins(IL-1 beta, TNF-alpha, IL-6, IL-12, CCL-5, IL-11, IL-10, IL-13) was evaluated by qPCR and showed changes in the expression of the inflammatory cytokines in the first two weeks after SCI.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neuropharmacology

ISSN

0028-3908

e-ISSN

—

Svazek periodika

155

Číslo periodika v rámci svazku

sep.

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

11

Strana od-do

54-64

Kód UT WoS článku

000474313900006

EID výsledku v databázi Scopus

2-s2.0-85066440987